Abstracts amounted to 75.8%. 56.5% of pts had hypertension and 29.7% were diabetic. Thirty-four percent of pts were diagnosed as obese with additional 44.2% of the pts' population being overweight. The prevalence of current smokers was 17.5% in total study population and 15.8% in post myocardial infraction pts. Except ACEI (70.6% vs. 69.5%) drugs such as ASA, LBA, statins were more frequently applied in secondary prevention group when compared with primary prevention pts (respectively 54.9% vs. 85.8%, 41.9 vs. 77.0%, 53.8 vs. 79 , stress echocardiography, angiography) were accepted. We constructed diagnostic 2 × 2-tables from diagnostic test characteristics (e.g., sensitivity, specificity) and performed a diagnostic meta-analysis using the inverse variance approach. RESULTS: Thirteen articles were identified matching the inclusion criteria. Four articles were excluded because of multiple reporting of data. From the 9 studies included, data for 717 observational units (i.e., patient or coronary lesion) were extracted. Pooled sensitivity of FFR was 82% (95%-CI: 77-86%), and specificity was 79% (74-83%). Diagnostic odds ratio was 16.5 (11.4-63.7). Excluding single studies did not affect these results. Subgroup analyses showed severity of disease reflected by the number of affected coronary vessels as an influential factor on test sensitivity (single-vessel-disease:
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DRUG-ELUTING STENT USE IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN LONG-TERM CLINICAL OUTCOMES
Eisenstein EL, Tuttle RH, Shaw LK, Anstrom KJ, Kong DF Duke Clinical Research Institute, Durham, NC, USA OBJECTIVE: Drug-eluting stents (DES) have become the principal coronary artery revascularization modality in the US; yet little is known about their long-term clinical outcomes versus bare-metal stents (BMS). We examined 2-year clinical event rates for BMS vs. DES in a practice-based population and compared results for patients with single-as well as multi-vessel coronary artery disease (CAD). METHODS: The study population includes Duke University Medical Center patients undergoing revascularization with BMS or DES between January 1, 2000 and May 31, 2005, with follow-up through August 17, 2006. Study outcomes examined are death, non-fatal myocardial infarction (MI), and target vessel revascularization (TVR), and their composites. RESULTS: We examined the data of 3678 BMS and 1689 DES patients. DES vs. BMS patients had more multivessel CAD (42.6% vs. 36.6%). At two years follow-up, DES vs. BMS patients had lower rates of mortality (7.8% vs. 8.6%), nonfatal MI (3.3% vs. 5.0%), and TVR (6.0% vs. 14.2%). This difference in DES vs. BMS TVR rate was observed in patients with 1-(5.5% vs. 13.0%), 2-(6.7% vs. 15.7%), and 3-vessel CAD (7.0% vs. 18.8%). After adjustment for differences in baseline characteristics using Cox proportional hazards modeling, DES vs. BMS use was associated with no difference in mortality; but with significant reductions in the composites of death or MI (HR = 0.81, 95% CI = 0.67, 0.98) and death, MI, or TVR (HR = 0.55, 95% CI = 0.47, 0.64). Event reduction in the adjusted models was not limited to 1-, 2-, or 3-vessel CAD patients. CON-CLUSIONS: The use of drug-eluting vs. bare-metal stents is associated with significant improvements in long-term clinical outcomes for patients with single-and multi-vessel coronary artery disease. Guidelines (JBS2, 2005) recommend patients be treated to a lower TC target of <4 mmol/L. An audit was conducted to determine the effect of the new guidelines on the proportion of patients achieving target cholesterol levels with rosuvastatin. METHODS: General Practice records were searched to identify patients who had been prescribed rosuvastatin 10 mg and the following data recorded: previous statin therapy, last cholesterol result on that statin and first cholesterol test on rosuvastatin 10 mg. RESULTS: A total of 508 patients who had previously been prescribed rosuvastatin 10 mg were identified. Of these 376 had both a pre-and post-rosuvastatin treatment total cholesterol test. The majority of patients were statin-naive (n = 253), the others had previously been prescribed atorvastatin, mean dose 14 mg (n = 102), simvastatin mean dose 19 mg (n = 22) or pravastatin mean dose 15 mg (n = 2). Prior to treatment with rosuvastatin 13% (49/376) had a TC <5 mmol/L, increasing to 81% (303/376) after treatment with rosuvastatin 10 mg. In previously statin naïve patients 82% (208/253) achieved TC <5 mmol/L on rosuvastatin compared to 77% (95/123) in patients who had previously been treated with another statin. On average patients experienced a 1.6 mmol/L (27%) reduction in TC (32% in statin naïve, 16% where statin changed). Improvements were also seen against JBS2 targets; patients with TC <4 mmol/L improved from 3% (11/376) prior to rosuvastatin to 35% (131/376) on rosuvastatin 10 mg (37% in statin naïve, 30% where statin changed). CONCLUSIONS:
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Rosuvastatin 10 mg was effective in the reduction of TC in a Scottish General Practice. The majority of patients were able to achieve SIGN targets and many patients also achieved the lower JBS2 targets. (AWMSG) recommends that at risk patients should be treated to a total cholesterol (TC) target of <5 mmol/L and low density lipoprotein-cholesterol (LDL-C) <3 mmol/L. Recent Joint British Societies Guidelines (JBS2, 2005) advise patients be treated to TC <4 mmol/L and LDL-C <2 mmol/L. An audit was conducted to determine the effect of the new guidelines on the proportion of patients achieving target cholesterol levels with rosuvastatin. METHODS: General Practice records were searched to identify patients who had been prescribed rosuvastatin 10 mg and the following data recorded: previous statin therapy, last cholesterol result on that statin and first cholesterol test on rosuvastatin. RESULTS: A total of 337 patients who had been prescribed rosuvastatin were identified. Of these 273 patients prescribed rosuvastatin 10 mg had both a pre-and post-rosuvastatin treatment TC result, 33 had LDL-C results. The majority of patients were statin-naive (195), others had previously been prescribed atorvastatin mean dose 18 mg (n = 45), simvastatin mean dose 20 mg (n = 29) or pravastatin mean dose 23 mg (n = 4). Prior to treatment with rosuvastatin, 11% (29/273) had a TC <5 mmol/L, increasing to 79% (215/273) after treatment with rosuvastatin 10 mg. On average patients experienced a 1.6 mmol/L (26%) reduction in TC. The proportion of patients with LDL-C <3 mmol/L improved from 12% (4/33) to 94% (31/33) on rosuvastatin. On average patients experienced a 1.6 mmol/L (42%) reduction in LDL-C. Improvements were also seen against JBS2 targets; patients with TC <4 mmol/L improved from 0% prior to rosuvastatin to 32% on rosuvastatin 10 mg and similarly patients with LDL-C <2 mmol/L improved from 0% to 39%. CONCLUSIONS: Rosuvastatin 10 mg wass effective in the reduction of TC and LDL-C in a Welsh general practice. The majority of patients were able to achieve AWMSG targets and many patients also achieve the recommended lower JBS2 targets. were identified from the UK DIN-LINK database. Patients with no dyslipidemic therapy in the 12 months preceding their initial statin prescription and an LDL-C or TC measurement less than 6 months before and at least 1 month after initiating statin therapy were included in the study. Adjusted percent LDL-C reductions and percent TC reductions were compared using linear regression techniques. RESULTS: A total of 2151 patients with complete LDL-C data were identified. Rosuvastatin (n = 159), atorvastatin (n = 836), simvastatin (n = 1107) and pravastatin (n = 49) groups were similar with respect to mean age (64.5, 64.4, 65.1 and 65.1 years respectively) and baseline LDL-C levels (4.4, 4.3, 4.3 and 4.0 mmol/L respectively). After adjusting for age, gender, baseline LDL-C, therapy duration and 2003 European guideline risk factors, patients initiated on rosuvastatin achieved a significantly greater percentage LDL-C reduction (44.8%; 95% confidence interval 42.1%-47.4%) than patients initiated on atorvastatin (40.4%; 39.2%-41.5%), simvastatin (36.5%; 35.5%-37.5%) or pravastatin (29.9%; 25.1%-34.5%): all p < 0.01. Similarly, in patients where complete TC data was available (n = 7070), patients initiated on rosuvastatin (n = 475) had a significantly greater adjusted percentage TC reduction (31.3%; 30.1%-32.5%) than patients initiated on atorvastatin (n = 2662; 28.2%; 27.7%-28.7%), simvastatin (n = 3665; 25.3%; 24.9%-25.7%) or pravastatin (n = 268; 20.7%; 19.1%-22.3%): all p < 0.0001. CONCLUSIONS: In patients newly initiated on usual start doses of statins in routine practice, rosuvastatin was more effective in lowering both LDL-C and TC than atorvastatin, simvastatin and pravastatin. Novartis Pharma AG, Basel, Switzerland OBJECTIVE: Low adherence to antihypertensive drug (AHT) treatment may limit patient's benefits in terms of a reduction of cardiovascular and cerebrovascular disease. This study investigated the relationship between persistence with antihypertensive drugs and risk of myocardial infarction (MI) or stroke in daily practice. METHODS: From the PHARMO record linkage system comprising, among other medical information, the medication histories and hospital discharge diagnoses of >2 million inhabitants in The Netherlands, new users of AHT were identified between 1993-2002. Persistence with AHT was determined by summing the number of days of continuous treatment (gaps between dispensings <60 days). Persistent patients remained on AHT for 24 months. The outcome of interest was the first hospital admission for MI or stroke occurring two or more years after initiation of AHT therapy. Patients were classified at high, intermediate or low cardiovascular risk based on other cardiovascular drug use and hospitalizations during the first two years of follow-up. RESULTS: The study included 98,485 patients of whom 16% were at high cardiovascular risk. About 50% (n = 48,548) of all patients were persistent with AHT for two years. Multivariate analyses showed that persistent users of AHT had a statistically significant lower risk for MI/stroke compared to non-persistent users (RRadj = 0.88; 95%CI: 0.82-0.94). The association was stronger in the low/intermediate risk group (RRadj = 0.85; 95%CI: 0.79-0.92) than in the high risk group (RRadj = 0.95; 95%CI: 0.83-1.09). CONCLUSION: Nonpersistent use of AHT in daily practice leads to increased risk of hospitalizations for MI or stroke.
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